Targeting the bone marrow microenvironment in acute leukemia.


Despite individual differences between certain leukemias, the overall survival rate in acute leukemia remains low at approximately 40%. Novel therapeutics, including targeted therapies like tyrosine kinase inhibitors, have been incorporated into treatment regimens, but most have failed at eradicating leukemic stem cells (LSCs). The causes of disease relapse… (More)
DOI: 10.1080/10428194.2018.1434886


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.